MSD is spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company (“NewCo”)

We have made the decision to separate into two growth companies: MSD and NewCo. By optimizing our human health portfolio, MSD can move closer to its aspiration of being the premier research-intensive biopharmaceutical company, while also properly prioritizing a set of products at NewCo that are important to public health and the patients who rely on them, and which present real opportunities for growth.

Kenneth C. Frazier
MSD Chairman and CEO

Better meeting the needs of patients and improving public health globally

  • Merck will continue to be the premier research-intensive biopharmaceutical company
  • Growth pillars, Oncology, Vaccines, Hospital, Animal Health
  • NewCo will unleash potential in women's health and other areas
  • Growth pillars, Woman's Health, Legacy Brands, Biosimilars